Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

174
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
174
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

234
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
234
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

237
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
237
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Asthma-I: Introduction01:29

Asthma-I: Introduction

2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

245
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
245

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient Safety Incidents Involving Sick Children in Primary Care in England and Wales: A Mixed Methods Analysis.

PLoS medicine·2017
Same author

Acid-suppressive medications during pregnancy and risk of asthma and allergy in children: A systematic review and meta-analysis.

The Journal of allergy and clinical immunology·2017
Same author

Establishing data-intensive healthcare: the case of Hospital Electronic Prescribing and Medicines Administration systems in Scotland.

Journal of innovation in health informatics·2017
Same author

Tightrope walking towards maximising secondary uses of digitised health data: a qualitative study.

Journal of innovation in health informatics·2017
Same author

A systematic scoping review of the domains and innovations in secondary uses of digitised health-related data.

Journal of innovation in health informatics·2017
Same author

Protocol for a systematic review to identify and weight the indicators of risk of asthma exacerbations in children aged 5-12 years.

NPJ primary care respiratory medicine·2017

Related Experiment Video

Updated: Jun 7, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K

Antidiabetic Medication and Asthma Attacks.

Bohee Lee1, Kenneth K C Man2, Ernie Wong1

  • 1National Heart and Lung Institute, Imperial College London, London, England.

JAMA Internal Medicine
|November 18, 2024
PubMed
Summary
This summary is machine-generated.

Metformin use in type 2 diabetes patients with asthma was linked to fewer asthma attacks. Adding glucagon-like peptide-1 receptor agonists (GLP-1RA) further reduced asthma exacerbations, independent of glycemic control or weight.

More Related Videos

Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

5.9K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Related Experiment Videos

Last Updated: Jun 7, 2025

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion
07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.2K
Acupuncture in a Rat Model of Asthma
07:14

Acupuncture in a Rat Model of Asthma

Published on: August 25, 2020

5.9K
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

25.7K

Area of Science:

  • Respiratory Medicine
  • Endocrinology
  • Clinical Epidemiology

Background:

  • Elevated BMI and type 2 diabetes are common in asthma patients, increasing asthma attack risk.
  • Experimental studies suggest metformin and GLP-1RA may reduce airway inflammation and hyperresponsiveness.
  • Limited epidemiological data exists on the impact of these diabetes medications on asthma exacerbations.

Purpose of the Study:

  • To assess the association between metformin and add-on antidiabetic medications with asthma attacks.
  • To investigate the role of GLP-1RA, DPP-4 inhibitors, sulfonylureas, SGLT2 inhibitors, and insulin.
  • To explore interactions between metabolic/asthma phenotypes and medication effects.

Main Methods:

  • Utilized UK CPRD Aurum data (2004-2020) with linked hospital admissions.
  • Employed a self-controlled case series (SCCS) and a metformin new user cohort (IPTW) for robust analysis.
  • Primary outcome: first asthma exacerbation within 12 months; secondary: add-on medication effects.

Main Results:

  • Metformin was associated with a reduced rate of asthma attacks in both SCCS (IRR 0.68) and IPTW (HR 0.76) analyses.
  • GLP-1RA showed an additive association with further reductions in asthma attacks (SCCS IRR 0.60).
  • No significant bias detected in negative control analyses; effects were independent of BMI, glycemic control, or asthma severity.

Conclusions:

  • Metformin use is associated with a lower incidence of asthma attacks in patients with type 2 diabetes.
  • GLP-1RA demonstrated an additive benefit in reducing asthma attacks.
  • These benefits appear to operate through mechanisms beyond glycemic control or weight loss across various asthma phenotypes.